



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	Asian Journal of Research in Medical and Pharmaceutical Sciences
Manuscript Number:	Ms_AJRIMPS_43956
Title of the Manuscript:	Prevalence and Susceptibility Analysis of Gram negative pathogens in Tertiary Care Hospital
New Title of the Manuscript:	Antibiotic Susceptibility profile and prevalence Pattern of of Gram negative pathogens in Tertiary Care Hospital
Type of Article:	Original Research Article

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
<p>Abstract: "CSE-1034 as the most susceptible drug" should be "CSE-1034 as the most effective drug"</p> <p>Line 52 – MBL is one type of carbapenemase. Eventually should be "ESBL and carbapenemase producing strains (including MBL)"</p> <p>Line 80 "Biochemical reactions were performed by inoculating the bacterial colony in a nutrient broth at 37°C for 2– 3 hours" – still not true.</p> <p>The author's comment "For sensitivity of Imipenem - Cilastatin combination, we refer to the zone diameter chart given for Imipenem in CLSI guidelines." should be stated in Materials and methods</p> <p>Interpretation of CSE-1034 diameter is still not clear, should be mentioned in methods</p> <p>E. coli from stool – not relevant (normal flora), unless some specific criteria are met (pathogenic E. coli, identified by agglutination / PCR, etc). Materials and methods should cover this aspect. K. pneumoniae from stool – the same idea...</p> <p>Line 120 and other places – "similar susceptibility of meropenem" – again there is a confusion between susceptibility (referring to bacteria) and activity of an antibiotic</p> <p>Table 4 – what AAE means?</p> <p>These methodological issues have to be seriously addressed and explained before publication</p>	<p><u>Response to comments</u></p> <ol style="list-style-type: none"> 1. Abstract: "CSE-1034 as the most susceptible drug" should be "CSE-1034 as the most effective drug" Done. 2. Line 52 – MBL is one type of carbapenemase. Eventually should be "ESBL and carbapenemase producing strains (including MBL)" Done. 3. Line 80 "Biochemical reactions were performed by inoculating the bacterial colony in a nutrient broth at 37°C for 2– 3 hours" – still not true. Done. 4. The author's comment "For sensitivity of Imipenem - Cilastatin combination, we refer to the zone diameter chart given for Imipenem in CLSI guidelines." should be stated in Materials and methods. Done. 5. Interpretation of CSE-1034 diameter is still not clear, should be mentioned in methods. Done. 6. E. coli from stool – not relevant (normal flora), unless some specific criteria are met (pathogenic E. coli, identified by agglutination / PCR, etc). Materials and methods should cover this aspect. K. pneumoniae from stool – the same idea... Done. 7. Line 120 and other places – "similar susceptibility of meropenem" – again there is a confusion between susceptibility (referring to bacteria) and activity of an antibiotic Done. 8. Table 4 – what AAE means? Addressed.